Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study

Background Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real‐world setting in Japan are limited. Methods and Re...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Koutaro Yokote, Junya Ako, Kazuo Kitagawa, Nobuhiro Osada, Feng Sheng, Masae Sonoda, Tamio Teramoto
Format: Artykuł
Język:English
Wydane: Wiley 2024-11-01
Seria:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Hasła przedmiotowe:
adverse event
evolocumab
familial hypercholesterolemia
hypercholesterolemia
LDL‐C–lowering therapy
Dostęp online:https://www.ahajournals.org/doi/10.1161/JAHA.124.035809

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.035809

Podobne zapisy